Recent Press Releases

Diabetes Scholars Foundation Announces 2014 Scholarship Recipients

Lilly Diabetes grants $200,000 for scholarships

ROLLING MEADOWS, Ill. and INDIANAPOLIS,

Abbott Hosts Conference Call for Second-Quarter Earnings

ABBOTT PARK, Ill., June 25, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2014 financial results on

Sinai Hospital Doctor's Research Shows Positive Long-term Outcomes of Medical Therapy for Cushing's Syndrome, a Devastating Rare Disease

Sinai Hospital Doctor's Research Shows Positive Long-term Outcomes of Medical Therapy for Cushing's Syndrome, a Devastating Rare Disease New study shows patients experienced significant, sustained...

Vyvanse(R) Patents Found to Be Infringed and Valid by U.S. District Court

LEXINGTON, Massachusetts, Jun 25, 2014 (PR Newswire Europe via COMTEX) -- LEXINGTON, Massachusetts, June 25, 2014 /PRNewswire/ -- Shire plc announces that Judge Stanley R. Chesler of the U.S....

AbbVie Inc. Statement regarding a possible offer for Shire plc

AbbVie Inc. Statement regarding a possible offer for Shire plc 25 June 2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY...

Abbott Receives CE Mark for TECNIS® Symfony Extended Range of Vision Intraocular Lens for Cataract Patients

ABBOTT PARK, Ill., June 24, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received CE Marking (Conformite Europeenne) in

Verizon Expands Access to Medical Care for Patients, With 'Verizon Virtual Visits'

New Mobile Health Product Allows Patients With Acute Conditions to See Clinicians via Smartphone, Tablet or Computer

NEW YORK,

Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and License Agreement

Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and License Agreement Takeda will withdraw the Omontys U.S. New Drug Application (NDA) Cupertino, CA (June...

Affymax Board Announces Decision to Dissolve the Company

Affymax Board Announces Decision to Dissolve the Company CUPERTINO, Calif., Jun 24, 2014 (BUSINESS WIRE) -- Affymax, Inc. (AFFY), a biopharmaceutical company, today announced that its Board of...

Merck Names Michael J. Holston as Future General Counsel; Will Succeed Bruce N. Kuhlik in July 2015

Merck Names Michael J. Holston as Future General Counsel; Will Succeed Bruce N. Kuhlik in July 2015 WHITEHOUSE STATION, N.J., Jun 23, 2014 (BUSINESS WIRE) -- Merck MRK +0.14% , known as MSD outside...

Endo to Acquire DAVA Pharmaceuticals

Adds high-margin marketed generics portfolio, robust near-term ANDA pipeline to Endo's existing generics portfolio Ability to leverage Endo's corporate platform and proven commercial...

Abbott to Acquire Veropharm

June 23, 2014 Abbott Park, Illinois (NYSE: ABT) — Abbott today announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer. Under the terms of the...

Abbott to Acquire Veropharm

ABBOTT PARK, Ill., June 23, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a definitive agreement to acquire Veropharm, a l

Eli Lilly and Company Collaborates with Public and Private Healthcare Organizations to Provide Medical Students an Opportunity to Explore Healthcare Outside the Traditional Learning Environment

Anthem Blue Cross and Blue Shield and Indiana Family & Social Services Administration (FSSA)offer students insights on access to healthcare

Cubist's SIVEXTRO™ (tedizolid phosphate) Approved in U.S. to Treat Serious Skin Infections—Including Those Caused by MRSA

Lexington, Mass., June 20, 2014 – Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today the U.S. Food and Drug Administration (FDA) approved SIVEXTRO™ (tedizolid phosphate) for the...

Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements

LAVAL, Quebec, Jun 23, 2014 (Canada NewsWire via COMTEX) -- Valeant Pharmaceuticals International, Inc. VRX +3.73% CA:VRX +3.78% today announced that, as promised, it has posted fact-based answers...

Allergan Board of Directors Unanimously Rejects Unsolicited Exchange Offer from Valeant

Board Determines Offer is Grossly Inadequate, Substantially Undervalues Allergan and Creates Significant Risks and Uncertainties for Allergan Stockholders Files 14D-9 with SEC Urging...

Bayer Receives Approval for Nexavar® (sorafenib) in Japan for Treatment of Differentiated Thyroid Cancer

Bayer Receives Approval for Nexavar® (sorafenib) in Japan for Treatment of Differentiated Thyroid Cancer Berlin, June 20, 2014 – Bayer HealthCare announced today that the Ministry of...

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CODE. THERE CAN BE NO CERTAINTY THAT ANY FIRM OFFER WI

LONDON, June 19, 2014 -- AbbVie Inc. ("AbbVie") notes the recent press speculation and confirms it made an indicative approach to Shire plc ("Shire") with a merger proposal which...